No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a:

Multiple Sclerosis Journal – Experimental, Translational and Clinical

Gavin Giovannoni¹  Eva Havrdová²  Giancarlo Comi³  Douglas L Arnold⁴  Krzysztof Selmaj⁵  Shibeshih Belachew⁶  Regine Buffels⁷  Stephen L Hauser⁷  Iain Bennett⁷  Hideki Garren⁷  Julie Napieralski⁸  Jian Han⁸  Laura Julian⁸  Ludwig Kappos⁹  Anthony Traboulsee^1,10  Amit Bar-Or^1,11  Fred Lublin^1,12  Hans-Peter Hartung^1,13 

[1] Department of Neurology University of California, San Francisco, USA;Department of Neurology and Center for Clinical Neuroscience, Charles University, Czech Republic;Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania, USA;Department of Neurology and Neurosurgery, McGill University, Canada;Department of Neurology, Icahn School of Medicine at Mount Sinai, USA;Division of Neurology, Department of Medicine, University of British Columbia, Canada;F. Hoffmann-La Roche Ltd, Switzerland;Genentech Inc, USA;Medical Faculty, Heinrich Heine University Düsseldorf, Germany;Medical University of Lodz, Poland;NeuroRx Research, Canada;Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, Switzerland;Neurology Department and INSPE-Institute of Experimental Neurology, Vita-Salute San Raffaele University, Italy

关键词: NEDA;    disease activity;    relapse;    disability progression;    MRI activity;   

DOI  :  10.1177/2055217318760642

学科分类：医学（综合）

来源: Sage Journals

【 授权许可】

CC BY-NC